Description du projet
Évaluation des effets des médicaments et des polluants sur la santé du fœtus
Le taux de naissances prématurées est en augmentation: en Europe, environ 75 % de tous les décès néonatals et 60 % de tous les décès infantiles concernent des enfants nés prématurément. Partant du principe que chaque femme enceinte doit vivre dans un environnement meilleur et plus sûr, le projet LIFESAVER, financé par l’UE, créera un nouveau système in vitro cloné numériquement pour émuler les conditions prénatales de transport des médicaments et des polluants à l’interface utérin/placentaire. Le système repose sur l’hybridation de technologies innovantes, intégrant des systèmes in silico et in vitro pour permettre le dépistage de produits chimiques et pharmaceutiques susceptibles d’affecter la santé des femmes enceintes, tout en réduisant les besoins en matière d’expérimentation animale, préclinique et clinique.
Objectif
In Europe about 75% of all neonatal deaths and 60% of all infant deaths occur in infants born preterm, and worldwide 450 neonatal deaths occur every hour. The number of preterm births is growing despite advances in medicine as more pregnancies are in the later age but also due to increasing environmental treats and lack of suitable treatments.
In the LIFESAVER vision, every pregnant woman must have a proper living environment with the minimal risks to the fetus, safeguarded with scientifically justified regulations in use and control of potentially risky chemical and medicinal products, leading to healthier quality lives of the babies, overarching for generations.
The LIFESAVER addresses the presently unmet societal and healthcare needs in creating and developing of a validated scientific knowledge base for the development and implementation of regulatory approaches relevant to maternal and fetal health. The objective is in creation of new, digitally cloned in vitro system for emulation of the pre-natal conditions in the vicinity of uterine/placental interface, capable of future high biofidelity prediction of safety and risk of substances towards unborn babies. LIFESAVER concept is based on an original idea of hybridization of several innovative technologies, integrating digital in silico/in vitro (biodigital twin) systems, enabling effective screening of chemicals and pharmaceuticals which might affect pregnant women health, reducing animal, preclinical and clinical testing, which is not presently possible with any other existing approaches to the same level of confidence.
The outcomes are in design, manufacturing and deployment of a platform having key components of in vitro placental tissue for sufficient emulation of typical prenatal conditions. This aims to provide a solid scientific rationale for new regulations for chemical and pharmaceutical use relevant for the Green Deal vision.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
38100 Trento
Italie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.